News brief­ing: Catal­ent, Mer­ck KGaA make big in­vest­ments in man­u­fac­tur­ing ops; J&J teams with Data­vant on da­ta shar­ing projects

We’re con­tin­u­ing to see big in­vest­ments in the glob­al bio­phar­ma man­u­fac­tur­ing in­fra­struc­ture.

Wednes­day morn­ing Catal­ent put out the word that it is in­vest­ing $130 mil­lion in its late-stage ops at its gene ther­a­py fa­cil­i­ty in Har­mans, MD. The con­tract man­u­fac­tur­er has been sink­ing a sig­nif­i­cant amount of mon­ey in­to gene ther­a­py as that field con­tin­ues to boom.

Mer­ck KGaA pre­ced­ed that an­nounce­ment with the news that the Ger­man bio­phar­ma play­er is trig­ger­ing a €59 mil­lion ex­pan­sion of its HPA­PI and ADC man­u­fac­tur­ing ca­pa­bil­i­ties and ca­pac­i­ty at its fa­cil­i­ty near Madi­son, WI. That move will add 50 new jobs as they ramp up work on the on­col­o­gy pipeline with new tech that al­lows con­tin­u­ous man­u­fac­tur­ing of AD­Cs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER